Symbols

ABVX

Abivax·NASDAQ

--(--)

ABVX Profile

Abivax Sa

A biotechnology company focused on harnessing the body's natural regulatory mechanisms to modulate the clinical stages of chronic inflammatory diseases

Industry

Biological Technology

Established Date

12/04/2013

Listing Date

10/20/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.abivax.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

7-11 boulevard Haussmann, 75009 Paris, France

Business

Introduction

Abivax Sa was incorporated on December 4, 2013 under the laws of France. The company is a clinical-stage biotechnology company focused on developing therapies that leverage the body's natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. Its lead drug candidate, obefazimod, is in Phase 3 development for the treatment of ulcerative colitis and is being developed for Crohn's disease.